How does the quality of phospholipidosis data influence the predictivity of structural alerts?

Journal of Chemical Information and Modeling

Volumn 54, Issue 8, 2014, Pages 2224-2232

  Przybylak, Katarzyna R ^a   Alzahrani, Abdullah Rzgallah ^a   Cronin, Mark T D ^a  

^a LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL DETECTION; GOLD METALLOGRAPHY; HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY;

DOSE DEPENDENCES; HIGH QUALITY DATA; MODEL-BASED OPC; POSITIVE CORRELATIONS; PREDICTIVE PERFORMANCE; STRUCTURAL FRAGMENTS; TARGET SPECIFICATIONS; UNITED STATES FOOD AND DRUG ADMINISTRATIONS;

QUALITY CONTROL;

DRUG; PHOSPHOLIPID;

AGONISTS; CHEMICAL DATABASE; CHEMICALLY INDUCED; CHEMISTRY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FOOD AND DRUG ADMINISTRATION; HUMAN; INFORMATION PROCESSING; LIPIDOSES; METABOLISM; QUANTITATIVE STRUCTURE ACTIVITY RELATION; UNITED STATES;

DATABASES, CHEMICAL; DATASETS AS TOPIC; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; LIPIDOSES; PHARMACEUTICAL PREPARATIONS; PHOSPHOLIPIDS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84906545251     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci500233k     Document Type: Article

References (56)

1. Reasor, M. J.; Hastings, K. L.; Ulrich, R. G. Drug-induced phospholipidosis: issues and future directions Expert Opin. Drug Saf. 2006, 5, 567-583
2. Johnson, W. J.; Warner, G. J.; Yancey, P. G.; Rothblat, G. H. Lysosomal metabolism of lipids Subcell. Biochem. 1996, 27, 239-293
3. Kodavanti, U. P.; Mehendale, H. M. Cationic amphiphilic drugs and phospholipid storage disorder Pharmacol. Rev. 1990, 42, 327-54
4. Goldman, S. D.; Funk, R. S.; Rajewski, R. A.; Krise, J. P.Mechanisms of amine accumulation in, and egress from, lysosomes Bioanalysis 2009, 1, 1445-59
5. Sawada, H.; Takami, K.; Asahi, S. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system Toxicol. Sci. 2005, 83, 282-292
6. Abe, A.; Hiraoka, M.; Shayman, J. A. A role for lysosomal phospholipase A2 in drug induced phospholipidosis Drug Metab. Lett. 2007, 1, 49-53
7. Lullmann-Rauch, R. Drug-induced lysosomal storage disorders Front. Biol. 1979, 48, 49-130
8. Nonoyama, T.; Fukuda, R. Drug-induced Phospholipidosis- Pathological Aspects and Its Prediction J. Toxicol. Pathol. 2008, 21, 9-24
9. Reasor, M. J. A review of the biology and toxicologic implication of the induction of lysosomal lamellar bodies by drugs Toxicol. Appl. Pharmacol. 1989, 97, 47-56
10. Halliwell, W. H. Cationic amphiphilic drug-induced phospholipidosis Toxicol. Pathol. 1997, 25, 53-60
11. Reasor, M. J.; Kacew, S. Drug-induced phospholipidosis: are there functional consequences? Exp. Biol. Med. 2001, 226, 825-30
12. Morelli, J. K.; Ciaccio, P. J. Differential cytotoxicity responses by dog and rat hepatocytes to phospholipogenic treatments J. Toxicol. 2013, 308594
13. Morelli, J. K.; Buehrle, M.; Pognan, F.; Barone, L. R.; Fieles, W.; Ciaccio, P. J. Validation of an ex vivo screen for phospholipidosis using a high-content biology platform Cell Biol. Toxicol. 2006, 22, 15-27
14. Hook, G. E. R. Alveolar proteinosis and phospholipidoses of the lungs Toxicol. Pathol. 1991, 19, 482-513
15. Lullmann, H.; Lullmann-Rauch, R.; Wassermann, O. Drug induced phospholipidosis Crit. Rev. Toxicol. 1975, 2, 185-218
16. Reasor, M. J.; Ogle, C. L.; Walker, E. R.; Kacew, S. Amioadrone-induced phospholipidosis in rat alveolar macrophages Am. Rev. Respir. Dis. 1988, 137, 510-518
17. Atienzar, F.; Gerets, H.; Dufrane, S.; Tilmant, K.; Cornet, M.; Dhalluin, S.; Ruty, B.; Rose, G.; Canning, M. Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells Toxicol. Sci. 2007, 96, 101-114
18. Przybylak, K. R.; Cronin, M. T. D. In silico studies of the relationship between chemical structure and drug induced phospholipidosis Mol. Inf. 2011, 30, 415-429
19. Ploemen, J. P.; Kelder, J.; Hafmans, T.; van de Sandt, H.; van Burgsteden, J. A.; Saleminki, P. J.; van Esch, E. Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis- inducing potential: A case study with structurally related piperazines Exp. Toxicol. Pathol. 2004, 55, 347-355
20. Pelletier, D. J.; Gehlhaar, D.; Tilloy-Ellul, A.; Johnson, T. O.; Greene, N. Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential J. Chem. Inf. Model. 2007, 47, 1196-1205
21. Sun, H.; Shahane, S.; Xia, M.; Austin, C. P.; Huang, R. Structure based model for the prediction of phospholipidosis induction potential of small molecules J. Chem. Inf. Model. 2012, 52, 1798-1805
22. Tomizawa, K.; Sugano, K.; Yamada, H.; Horii, I. Physicochemical and cell-based approach for early screening of phospholipidosis inducing potential J. Toxicol. Sci. 2006, 31, 315-324
23. Valco, K.; Du, C. M.; Bevan, C. D.; Reynolds, D. P.; Abraham, M. H. Rapid-gradient HPLC method for measuring drug interactions with immobilized artificial membrane: comparison with other lipophilicity measures J. Pharm. Sci. 2000, 89, 1085-1096
24. Vitovic, P.; Alakoskela, J. M.; Kinnunen, K. J. Assessment of drug-lipid complex formation by a high throughput Langmuir-Balance and correlation to phospholipidosis J. Med. Chem. 2008, 51, 1842-1848
25. Hanumegowda, U. M.; Wenke, G.; Regueiro-Ren, A.; Yordanova, R.; Corradi, J. P.; Adams, S. P. Phospholidosis as a function of basicity, liphophilicity and volume of distribution of compound Chem. Res. Toxicol. 2010, 23, 749-55
26. Kuroda, Y.; Saito, M. Prediction of phospholipidosis-inducing potential of drugs by in vitro biochemical and physicochemical assays followed by multivariate analysis Toxicol. in vitro 2010, 24, 661-668
27. Kruhlak, N. L.; Choi, S. S.; Contrera, J. F.; Weaver, J. L.; Willard, J. M.; Hastings, K. L.; Sancilio, L. F. Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models Toxicol. Mech. Methods 2008, 18, 217-27
28. Choi, S. S.; Kim, J. S.; Valerio, L. G., Jr.; Sadrieh, N. In silico modeling to predict drug-induced phospholipidosis Toxicol. Appl. Pharmacol. 2013, 269, 195-204
29. Lowe, R.; Glen, R. C.; Mitchell, J. B. Predicting phospholipidosis using machine learning Mol. Pharmaceutics 2010, 7, 1708-14
30. Van Bambeke, F.; Gerbaux, C.; Michot, J. M.; d'Yvoire, M. B.; Montenez, J. P.; Tulkens, P. M. Lysosomal alterations induced in cultured rat fibroblasts by long-term exposure to low concentrations of azithromycin J. Antimicrob. Chemother. 1998, 42, 761-767
31. Hostetler, K.; Vande Berg, J.; Aldern, K.; Brophy, G. Effect of amiodarone on the phospholipid and lamellar body content of lymphoblasts in vitro and peripheral blood lymphocytes in vivo Biochem. Pharmacol. 1991, 41, 1007-1013
32. Pospischil, A.; Walter, P.; Dingemanse, J. Phospholipidosis in healthy subjects participating in clinical studies: ultrastructural findings in white blood cells Exp. Toxicol. Pathol. 2010, 62, 567-571
33. Casartelli, A.; Bonato, M.; Cristofori, P. A cell-based approach for the early assessment of the phospholipidogenic potential in pharmaceutical research and drug development Cell Biol. Toxicol. 2003, 19, 161-176
34. Xia, Z.; Appelkvist, E. L.; Depierre, J. W.; Nassberger, L. Tricyclic antidepressant-induced lipidosis in human peripheral monocytes in vitro, as well as in a monocyte-derived cell line, as monitored by spectrofluorimetry and flow cytometry after staining with Nile red Biochem. Pharmacol. 1997, 53, 1521-1532
35. Gum, R. J.; Hickman, D.; Fagerland, J. A.; Heindel, M. A.; Gagne, G. D.; Schmidt, J. M.; Michaelides, M. R.; Davidsen, S. K.; Ulrich, R. G. Analysis of two matrix metalloproteinase inhibitors and their metabolites for induction of phospholipidosis in rat and human hepatocytes(1) Biochem. Pharmacol. 2001, 62, 1661-1673
36. Ulrich, R. G.; Kligore, K. S.; Sun, E. L.; Cramer, C. T.; Ginsberg, L. C. An in vitro fluorescence assay for the detection of drug-induced cytoplasmic lamellar bodies Toxicol. Meth. 1991, 1, 89-105
37. Kasahara, T.; Tomita, K.; Murano, H.; Harada, T.; Tsubakimoto, K.; Ogihara, T.; Ohnishi, S.; Kakinuma, C. Establishment of an in vitro high-throughput screening assay for etecting phospholipidosis-inducing potential Toxicol. Sci. 2006, 90, 133-141
38. Sun, M.; Zhao, C.; Gfesser, G. A.; Thiffault, C.; Miller, T. R.; Marsh, K.; Wetter, J.; Curtis, M.; Faghih, R.; Esbenshade, T. A.; Hancock, A. A.; Cowart, M. Synthesis and SAR of 5-Amino- and 5-(Aminomethyl)benzofuran Histamine H3 Receptor Antagonists with Improved Potency J. Med. Chem. 2005, 48, 6482-6490
39. Mesens, N.; Steemans, M.; Hansen, E.; Peters, A.; Verheyen, G.; Vanparys, P. A 96-well flow cytometric screening assay for detecting in vitro phospholipidosis-induction in the drug discovery phase Toxicol. in vitro. 2009, 23, 217-226
40. Bhandari, N.; Figueroa, D. J.; Lawrence, J. W.; Gerhold, D. L. Phospholipidosis assay in HepG2 cells and rat or rhesus hepatocytes using phospholipid probe NBD-PE Assay Drug Dev. Technol. 2008, 6, 407-19
41. van de Water, F. M.; Havinga, J.; Ravesloot, W. T.; Horbach, G. J. M. J.; Schoonen, W. G. E. J. High content screening analysis of phospholipidosis: Validation of a 96-well assay with CHO-K1 and HepG2 cells for the prediction of in vivo based phospholipidosis Toxicol. in vitro. 2011, 25, 870-1882
42. Muehlbacher, M.; Tripal, P.; Roas, F.; Kornhuber, J. Identification of Drugs Inducing Phospholipidosis by Novel in vitro Data Chem. Med. Chem. 2012, 7, 1925-1934
43. Nioi, P.; Perry, B. K.; Wang, E. J.; Gu, Y. Z.; Snyder, R. D. In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies Toxicol. Sci. 2007, 99, 162-173
44. Goracci, L.; Ceccarelli, M.; Bonelli, D.; Cruciani, G. Modeling phospholipidosis induction: reliability and warnings J. Chem. Inf. Model. 2013, 53, 1436-1446
45. Zhou, L.; Geraci, G.; Hess, S.; Yang, L.; Wang, J.; Argikar, U. Predicting phospholipidosis: a fluorescence noncell based in vitro assay for the determination of drug-phospholipid complex formation in early drug discovery Anal. Chem. 2011, 83, 6980-6987
46. Jiang, Z.; Reilly, J. Chromatography approaches for early screening of the phospholipidosis-inducing potential of pharmaceuticals J. Pharm. Biomed. Anal. 2012, 61, 184-190
47. Balogh, G. T.; Müller, J.; Könczöl, á. pH-gradient PAMPA-based in vitro model assay for drug-induced phospholipidosis in early stage of drug discovery Eur. J. Pharm. Sci. 2013, 49, 81-89
48. Cronin, M. T. D. Finding the Data to Develop and Evaluate (Q)SARs and populate categories for toxicity prediction. In In silico Toxicology: Principles and Applications; Cronin, M. T. D.; Madden, J. C., Eds.; The Royal Society of Chemistry: Cambridge, United Kingdom, 2010; pp 31-56.
49. Cronin, M. T. D.; Schultz, T. W. Pitfalls in QSAR J. Mol. Struc.-THEOCHEM. 2003, 622, 39-51
50. Orogo, A. M.; Choi, S. S.; Minnier, B. L.; Kruhlak, N. L. Construction and consensus performance of (Q)SAR models for predicting phospholipidosis using a dataset of 743 compounds Mol. Inf. 2012, 31, 725-739
51. Berthold, M. R.; Cebron, N.; Dill, F.; Gabriel, T. R.; Kötter, T.; Meinl, T.; Ohl, P.; Sieb, C.; Thiel, K.; Wiswedel, B. KNIME: The Konstanz Information Miner. In Studies in Classification, Data Analysis, and Knowledge Organization; Preisach, C.; Burkhardt, H.; Schmidt-Thieme, L.; Decker, R., Eds.; Springer: Berlin Heidelberg, 2008; pp 319-326.
52. Rowe, P. H. Statistical Methods for Continuous Measured Endpoints in In silico Toxicology. In In silico Toxicology: Principles and Applications; Cronin, M. T. D.; Madden, J. C., Eds.; The Royal Society of Chemistry: Cambridge, United Kingdom, 2010; pp 252-273.
53. Seki, S.; Itagaki, S.; Kobayashi, M.; Hirano, T.; Iseki, K. Amiodarone increases the accumulation of DEA in a human alveolar epithelium-derived cell line Biol. Pharm. Bull. 2008, 31, 1449-1452
54. Kapatou, E.; Skyrlas, A.; Agelaki, M. G.; Pantos, C.; Kolettis, T. M.; Malamou-Mitsi, V. Amiodarone attenuates apoptosis, but induces phospholipidosis in rat alveolar epithelial cells J. Physiol. Pharmacol. 2010, 61, 671-677
55. Kudo, S.; Umehara, K.; Hosokawa, M.; Miyamoto, G.; Chiba, K.; Satoh, T. Phenacetin deacetylase activity in human liver microsomes: distribution, kinetics, and chemical inhibition and stimulation J. Pharmacol Exp Therap. 2000, 294, 80-88
56. Kelly, D. W.; Holder, C. L.; Korfmacher, W. A.; Getek, T. A.; Lay, J. O., Jr.; Casciano, D. A.; Shaddock, J. G.; Duhart, H. M.; Slikker, W., Jr. Metabolism of methapyrilene by Fischer-344 rat and B6C3F1 mouse hepatocytes Xenobiotica 1992, 22, 1367-1381